Company: ARWR
Filing Date: 2025-03-07
Form Type: 424B7
Source: 0001193125-25-049889
Chunk: 19

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-03-07
Form: 424B7
Chunk 19
---
 fix the rights, preferences, privileges, qualifications and
restrictions granted to or imposed upon the preferred stock, including but not limited to dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any or all of which may be
greater than the rights of our common stock.

If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications
and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designations relating to that series. If we issue preferred stock, we will incorporate by reference
into the registration statement of which this prospectus is a part the form of any certificate of designations that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We
urge you to read the prospectus supplement related to any series of preferred stock we may offer, as well as the complete certificate of designations that contains the terms of the applicable series of preferred stock.

Delaware Anti-Takeover Law

We are
subject to Section 203 of the General Corporation Law of the State of Delaware (the “DGCL”). Section 203 of the DGCL generally prohibits a public Delaware corporation from engaging in a “business

6

combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

| • |     | prior to the date of the transaction, the board of directors of the corporation approved either the business 
 combination or the transaction that resulted in the stockholder becoming an interested stockholder;          |

| • |     | the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the                                                                                                                             
 transaction commenced, excluding for purposes of determining the number of shares outstanding (1) shares owned by persons who are directors and also officers and (2) shares owned by employee stock plans in which employee participants do 
 not have the right to determine whether shares held subject to the plan will be tendered in a tender or exchange offer; or                                                                                                                   |

| • |     | on or subsequent to the date of the transaction, the business combination is approved by the board and authorized                                                                                         
 at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by